PropertyValue
?:abstract
  • At present, there are no specific targeted drugs for the treatment of pneumonia (COVID-19) caused by the novel coronavirus (SARS-CoV-2). Interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate were chosen as off-label use, and remdesivir was chosen as compassionate use. This paper reviewed the behavior of the two medication response to the new major infectious disease.
is ?:annotates of
?:creator
?:journal
  • Journal_of_Pharmaceutical_Practice
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Clinical medication response under new major infectious disease: off-label use and compassionate use/ 药学实践杂志
?:type
?:who_covidence_id
  • #863485
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/h2974jbk>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/h2974jbk>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all